Sort by
Items per page

Send to

Choose Destination

Best matches for Roché H:

Nutritional modulation of metabolic inflammation. Kirwan AM et al. Biochem Soc Trans. (2017)

Fatty Acids and NLRP3 Inflammasome-Mediated Inflammation in Metabolic Tissues. Ralston JC et al. Annu Rev Nutr. (2017)

Dermatological adverse events with taxane chemotherapy. Sibaud V et al. Eur J Dermatol. (2016)

Search results

Items: 1 to 20 of 537


PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.

Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N, Lozano N, Lacaze JL, Pouderoux S, Gladieff L, Romieu G, Roché H, Filleron T, Lamy PJ.

Breast Cancer Res Treat. 2019 Jul 11. doi: 10.1007/s10549-019-05349-y. [Epub ahead of print]


6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators.

Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6.


Effects of dietary fat on insulin secretion in subjects with the metabolic syndrome.

Gulseth HL, Gjelstad IMF, Tiereny AC, McCarthy D, Lovegrove JA, Defoort C, Blaak EE, Lopez-Miranda J, Dembinska-Kiec A, Risérus U, Roche HM, Drevon CA, Birkeland KI.

Eur J Endocrinol. 2019 May 1;180(5):321-328. doi: 10.1530/EJE-19-0022.


Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment.

Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roché H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J, Campone M, Verrièle V, Lelièvre E, Guette C, Coqueret O.

Cell Death Dis. 2019 Feb 27;10(3):199. doi: 10.1038/s41419-019-1406-7.


Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F.

Clin Pharmacol Ther. 2019 Feb 20. doi: 10.1002/cpt.1404. [Epub ahead of print]


Dietary modulation of energy homoeostasis and metabolic-inflammation.

Roche HM.

Proc Nutr Soc. 2019 Feb 1:1-6. doi: 10.1017/S0029665118002872. [Epub ahead of print]


Hydroxylase Inhibition Selectively Induces Cell Death in Monocytes.

Crifo B, Schaible B, Brown E, Halligan DN, Scholz CC, Fitzpatrick SF, Kirwan A, Roche HM, Criscuoli M, Naldini A, Giffney H, Crean D, Blanco A, Cavadas MA, Cummins EP, Fabian Z, Taylor CT.

J Immunol. 2019 Mar 1;202(5):1521-1530. doi: 10.4049/jimmunol.1800912. Epub 2019 Jan 30.


Dietary fat composition: replacement of saturated fatty acids with PUFA as a public health strategy, with an emphasis on α-linolenic acid.

Lenighan YM, McNulty BA, Roche HM.

Proc Nutr Soc. 2019 May;78(2):234-245. doi: 10.1017/S0029665118002793. Epub 2019 Jan 11.


SerpinA3N is a novel hypothalamic gene upregulated by a high-fat diet and leptin in mice.

Sergi D, Campbell FM, Grant C, Morris AC, Bachmair EM, Koch C, McLean FH, Muller A, Hoggard N, de Roos B, Porteiro B, Boekschoten MV, McGillicuddy FC, Kahn D, Nicol P, Benzler J, Mayer CD, Drew JE, Roche HM, Muller M, Nogueiras R, Dieguez C, Tups A, Williams LM.

Genes Nutr. 2018 Nov 29;13:28. doi: 10.1186/s12263-018-0619-1. eCollection 2018.


Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism.

Hughes MF, Lenighan YM, Godson C, Roche HM.

Front Cardiovasc Med. 2018 Nov 6;5:148. doi: 10.3389/fcvm.2018.00148. eCollection 2018. Review.


Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).

Roché H, Eymard JC, Radji A, Prevost A, Diab R, Lamuraglia M, Soumoudronga RF, Gasnereau I, Toledano A.

BMC Cancer. 2018 Nov 16;18(1):1127. doi: 10.1186/s12885-018-4986-1.


Nutritionally Derived Metabolic Cues Typical of the Obese Microenvironment Increase Cholesterol Efflux Capacity of Adipose Tissue Macrophages.

O'Reilly ME, Kajani S, Ralston JC, Lenighan YM, Roche HM, McGillicuddy FC.

Mol Nutr Food Res. 2019 Jan;63(2):e1800713. doi: 10.1002/mnfr.201800713. Epub 2018 Nov 20.


Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation.

Lyons CL, Roche HM.

Int J Mol Sci. 2018 Oct 9;19(10). pii: E3092. doi: 10.3390/ijms19103092. Review.


UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

Campone M, Lacroix-Triki M, Roca L, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy C, Desmoulins I, Bachelot T, Winston T, Eymard JC, Uwer L, Duhoux FP, Verhoeven D, Jaubert D, Coeffic D, Orfeuvre H, Canon JL, Asselain B, Martin AL, Lemonnier J, Roché H.

Eur J Cancer. 2018 Nov;103:184-194. doi: 10.1016/j.ejca.2018.06.025. Epub 2018 Sep 26.


Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials.

Pistilli B, Mazouni C, Zingarello A, Faron M, Saghatchian M, Grynberg M, Spielmann M, Kerbrat P, Roché H, Lorgis V, Bachelot T, Campone M, Levy C, Gonçalves A, Lesur A, Veyret C, Vanlemmens L, Lemonnier J, Delaloge S.

Clin Breast Cancer. 2019 Feb;19(1):63-70. doi: 10.1016/j.clbc.2018.08.005. Epub 2018 Aug 23.


A proteomic signature that reflects pancreatic beta-cell function.

Curran AM, Scott-Boyer MP, Kaput J, Ryan MF, Drummond E, Gibney ER, Gibney MJ, Roche HM, Brennan L.

PLoS One. 2018 Aug 30;13(8):e0202727. doi: 10.1371/journal.pone.0202727. eCollection 2018.


Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.

Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L.

Clin Breast Cancer. 2018 Dec;18(6):489-497. doi: 10.1016/j.clbc.2018.07.024. Epub 2018 Aug 4.


Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.

Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.


Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.

N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.


Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.

Sarradin V, Dalenc F, Sibaud V, Tournier E, Roché H.

Clin Breast Cancer. 2018 Oct;18(5):e743-e746. doi: 10.1016/j.clbc.2018.06.009. Epub 2018 Jun 18. No abstract available.


Supplemental Content

Loading ...
Support Center